Last reviewed 2026-04-19 · How we verify

Mid dose ANAVEX2-73

Anavex Life Sciences Corp. · Phase 2 active Small molecule

Mid dose ANAVEX2-73 is a Small molecule drug developed by Anavex Life Sciences Corp.. It is currently in Phase 2 development.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Mid dose ANAVEX2-73
Sponsor	Anavex Life Sciences Corp.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ANAVEX2-73 for Treatment of Early Alzheimer's Disease (PHASE2, PHASE3)
ANAVEX2-73 Study in Parkinson's Disease Dementia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mid dose ANAVEX2-73 CI brief — competitive landscape report
Mid dose ANAVEX2-73 updates RSS · CI watch RSS
Anavex Life Sciences Corp. portfolio CI

Frequently asked questions about Mid dose ANAVEX2-73

What is Mid dose ANAVEX2-73?

Mid dose ANAVEX2-73 is a Small molecule drug developed by Anavex Life Sciences Corp..

Who makes Mid dose ANAVEX2-73?

Mid dose ANAVEX2-73 is developed by Anavex Life Sciences Corp. (see full Anavex Life Sciences Corp. pipeline at /company/anavex-life-sciences-corp).

What development phase is Mid dose ANAVEX2-73 in?

Mid dose ANAVEX2-73 is in Phase 2.

Manufacturer: Anavex Life Sciences Corp. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing